Clinical Trial Update: A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SAR443820 for reducing serum neurofilament levels in adults with multiple sclerosis has been terminated, and results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• SAR443820

Snippet

Sponsor: Sanofi | Conditions: Multiple Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2025-10-15